Martina Vincenzi, Amin Kremic, Appoline Jouve, Roberta Lattanzi, Rossella Miele, Mohamed Benharouga, Nadia Alfaidy-Benharouga, Stephanie Migrenne-Li, Anumantha G Kanthasamy, Marimelia Porcionatto, Napoleone Ferrara, Igor V Tetko, Laurent Désaubry, Canan G Nebigil
The prokineticins (PKs) were discovered approximately 20 years ago as small peptides inducing gut contractility. Today, they are established as angiogenic, anorectic and proinflammatory cytokines, chemokines, hormones and neuropeptides involved in variety of physiological and pathophysiological pathways. Their altered expression or mutations implicated in several diseases make them a potential biomarker. Their G-protein coupled receptors (GPCRs), PKR1 and PKR2 have divergent roles that can be therapeutic target for treatment of cardiovascular, metabolic, and neural diseases as well as pain and cancer...
September 8, 2023: Pharmacological Reviews